We serve Chemical Name:(2-Chloro-4-fluoro-5-methoxyphenyl)boronic acid CAS:1256355-46-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(2-Chloro-4-fluoro-5-methoxyphenyl)boronic acid
CAS.NO:1256355-46-0
Synonyms:2-chloro-4-fluoro-5-methoxyphenylboronic acid
Molecular Formula:C7H7BClFO3
Molecular Weight:204.39100
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:49.69000
Exact Mass:204.01600
LogP:0.16750
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-chloro-4-fluoro-5-methoxyphenylboronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-chloro-4-fluoro-5-methoxyphenylboronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-chloro-4-fluoro-5-methoxyphenylboronic acid Use and application,2-chloro-4-fluoro-5-methoxyphenylboronic acid technical grade,usp/ep/jp grade.
Related News: Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. (2-Chloro-4-fluoro-5-methoxyphenyl)boronic acid manufacturer The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. (2-Chloro-4-fluoro-5-methoxyphenyl)boronic acid supplier The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. (2-Chloro-4-fluoro-5-methoxyphenyl)boronic acid vendor The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. (2-Chloro-4-fluoro-5-methoxyphenyl)boronic acid factory Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs.
